JP2023089012A5 - - Google Patents

Download PDF

Info

Publication number
JP2023089012A5
JP2023089012A5 JP2023048083A JP2023048083A JP2023089012A5 JP 2023089012 A5 JP2023089012 A5 JP 2023089012A5 JP 2023048083 A JP2023048083 A JP 2023048083A JP 2023048083 A JP2023048083 A JP 2023048083A JP 2023089012 A5 JP2023089012 A5 JP 2023089012A5
Authority
JP
Japan
Prior art keywords
compound
compound according
treatment
salt
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023048083A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023089012A (ja
JP7584553B2 (ja
Filing date
Publication date
Priority claimed from JP2019502675A external-priority patent/JP7030776B2/ja
Application filed filed Critical
Publication of JP2023089012A publication Critical patent/JP2023089012A/ja
Publication of JP2023089012A5 publication Critical patent/JP2023089012A5/ja
Priority to JP2024193634A priority Critical patent/JP7834830B2/ja
Application granted granted Critical
Publication of JP7584553B2 publication Critical patent/JP7584553B2/ja
Priority to JP2026038716A priority patent/JP2026120530A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023048083A 2016-07-20 2023-03-24 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用 Active JP7584553B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024193634A JP7834830B2 (ja) 2016-07-20 2024-11-05 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用
JP2026038716A JP2026120530A (ja) 2016-07-20 2026-03-11 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662364620P 2016-07-20 2016-07-20
US62/364,620 2016-07-20
JP2019502675A JP7030776B2 (ja) 2016-07-20 2017-07-18 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用
PCT/CN2017/093385 WO2018014829A1 (en) 2016-07-20 2017-07-18 Aminopyridine derivatives and their use as selective alk-2 inhibitors
JP2022025894A JP7253086B2 (ja) 2016-07-20 2022-02-22 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022025894A Division JP7253086B2 (ja) 2016-07-20 2022-02-22 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024193634A Division JP7834830B2 (ja) 2016-07-20 2024-11-05 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用

Publications (3)

Publication Number Publication Date
JP2023089012A JP2023089012A (ja) 2023-06-27
JP2023089012A5 true JP2023089012A5 (cg-RX-API-DMAC7.html) 2023-11-24
JP7584553B2 JP7584553B2 (ja) 2024-11-15

Family

ID=60991950

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2019502675A Active JP7030776B2 (ja) 2016-07-20 2017-07-18 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用
JP2022025894A Active JP7253086B2 (ja) 2016-07-20 2022-02-22 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用
JP2023048083A Active JP7584553B2 (ja) 2016-07-20 2023-03-24 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用
JP2024193634A Active JP7834830B2 (ja) 2016-07-20 2024-11-05 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用
JP2026038716A Pending JP2026120530A (ja) 2016-07-20 2026-03-11 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2019502675A Active JP7030776B2 (ja) 2016-07-20 2017-07-18 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用
JP2022025894A Active JP7253086B2 (ja) 2016-07-20 2022-02-22 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024193634A Active JP7834830B2 (ja) 2016-07-20 2024-11-05 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用
JP2026038716A Pending JP2026120530A (ja) 2016-07-20 2026-03-11 アミノピリジン誘導体およびそれらの選択的alk-2阻害剤としての使用

Country Status (25)

Country Link
US (4) US10710980B2 (cg-RX-API-DMAC7.html)
EP (3) EP3971177B1 (cg-RX-API-DMAC7.html)
JP (5) JP7030776B2 (cg-RX-API-DMAC7.html)
KR (7) KR102359707B1 (cg-RX-API-DMAC7.html)
CN (2) CN109641871B (cg-RX-API-DMAC7.html)
AR (1) AR109108A1 (cg-RX-API-DMAC7.html)
AU (5) AU2017298187B2 (cg-RX-API-DMAC7.html)
CY (1) CY1124967T1 (cg-RX-API-DMAC7.html)
DK (2) DK3487851T3 (cg-RX-API-DMAC7.html)
EA (2) EA037520B1 (cg-RX-API-DMAC7.html)
ES (2) ES2902521T3 (cg-RX-API-DMAC7.html)
FI (1) FI3971177T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20211868T1 (cg-RX-API-DMAC7.html)
HU (2) HUE067992T2 (cg-RX-API-DMAC7.html)
LT (2) LT3971177T (cg-RX-API-DMAC7.html)
MX (2) MX388518B (cg-RX-API-DMAC7.html)
PL (2) PL3487851T3 (cg-RX-API-DMAC7.html)
PT (2) PT3971177T (cg-RX-API-DMAC7.html)
RS (2) RS62819B1 (cg-RX-API-DMAC7.html)
RU (1) RU2747318C2 (cg-RX-API-DMAC7.html)
SI (2) SI3971177T1 (cg-RX-API-DMAC7.html)
SM (2) SMT202100723T1 (cg-RX-API-DMAC7.html)
TW (5) TWI712598B (cg-RX-API-DMAC7.html)
UY (1) UY37331A (cg-RX-API-DMAC7.html)
WO (1) WO2018014829A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102359707B1 (ko) * 2016-07-20 2022-02-09 노파르티스 아게 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
TW202131926A (zh) 2019-11-22 2021-09-01 美商英塞特公司 包含alk2抑制劑及jak2抑制劑的組合療法
CN111170893B (zh) * 2020-01-19 2022-04-26 郑州依米花手性药物研究有限公司 Lefamulin的中间体化合物及其在Lefamulin制备中的应用
IL298767A (en) * 2020-06-16 2023-02-01 Incyte Corp ALK2 inhibitors for the treatment of anemia
KR102913358B1 (ko) * 2020-10-29 2026-01-14 주식회사 엘지화학 중수소화 화합물의 분석방법, 소자 제조용 중수소화 화합물의 선별방법 및 전자 소자의 제조방법
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
WO2023198114A1 (zh) * 2022-04-13 2023-10-19 杭州邦顺制药有限公司 Alk2激酶抑制剂

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077290A (en) 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
NZ257631A (en) 1992-11-17 1996-03-26 Ludwig Inst Cancer Res Serine/threonine kinase domain-containing protein, dna and hosts therefor
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
US6914058B2 (en) * 2002-01-18 2005-07-05 Dr. Reddy's Laboratories, Limited Antibacterial compounds: process for their preparation and pharmaceutical compositions containing them
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2003234464B2 (en) 2002-05-03 2009-06-04 Exelixis, Inc. Protein kinase modulators and methods of use
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
US20040067985A1 (en) 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
SE0203753D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
WO2004092727A2 (en) 2003-04-11 2004-10-28 Structural Genomix, Inc. Compound libraries and methods for drug discovery
JP4198183B2 (ja) 2004-05-27 2008-12-17 ファイザー・インク 選択的ドーパミンd3アゴニストとしてのアミノピリジン誘導体
SA05260265A (ar) 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
RU2007141401A (ru) 2005-04-08 2009-05-20 ЭЙСАЙ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. (JP) Терапевтический агент для лечения дискинезии
WO2007011760A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
GB0517175D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
PE20071241A1 (es) * 2006-01-17 2008-01-14 Schering Corp Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios
US8895711B2 (en) 2006-04-18 2014-11-25 The Trustees Of The University Of Pennsylvania Mutated ACVR1 for diagnosis and treatment of Fibrodyplasia Ossificans Progressiva (FOP)
EP2069313A2 (en) 2006-06-29 2009-06-17 Alantos Pharmaceuticals Holdings, Inc. Metalloprotease inhibitors
CN101627055A (zh) 2006-09-05 2010-01-13 梅达雷克斯公司 骨形成蛋白及其受体的抗体以及它们的使用方法
EP2270229A1 (en) 2006-09-12 2011-01-05 The General Hospital Corporation Inhibitors of bone morphogenetic protein (BMP) signalling for therapeutical purposes
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
BRPI0914891A2 (pt) 2008-06-20 2015-11-24 Metabolex Inc agonistas de aril gpr119 e usos dos mesmos
PH12013500294A1 (en) 2010-08-20 2017-08-23 Wyeth Llc Designer osteogenic proteins
AR084731A1 (es) 2010-12-06 2013-06-05 Piramal Life Sciences Ltd Derivados de imidazoquinolina sustituidos
WO2012087938A1 (en) 2010-12-20 2012-06-28 Glaxosmithkline Llc Quinazolinone derivatives as antiviral agents
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
LT2714677T (lt) 2011-05-23 2018-12-10 Merck Patent Gmbh Piridino ir pirazino dariniai
DK2753605T3 (da) 2011-09-09 2019-06-17 Lantheus Medical Imaging Inc Sammensætninger, fremgangsmåder, og systemer til syntesen og anvendelsen af billeddannelsesmidler
JP6430383B2 (ja) * 2012-09-28 2018-11-28 ヴァンダービルト ユニバーシティーVanderbilt University 選択的bmp阻害剤としての縮合複素環化合物
EP2964651A4 (en) * 2013-03-04 2016-11-30 Brigham & Womens Hospital BMP HEMMER AND METHOD OF USE THEREOF
PT2970205T (pt) * 2013-03-14 2019-08-26 Tolero Pharmaceuticals Inc Inibidores da jak2 e da alk2 e métodos para a sua utilização
JP6542192B2 (ja) 2013-03-14 2019-07-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. Bmp阻害剤およびその使用方法
US10329270B2 (en) 2013-10-21 2019-06-25 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
WO2015152183A1 (ja) 2014-03-31 2015-10-08 大日本住友製薬株式会社 進行性骨化性線維異形成症の予防剤及び治療剤
ES2907461T3 (es) 2015-01-20 2022-04-25 Boehringer Ingelheim Animal Health Usa Inc Compuestos antihelmínticos, composiciones y procedimientos de uso de los mismos
EP3344613B1 (en) 2015-08-31 2020-03-04 Dong-A Socio Holdings Co., Ltd. Heteroaryl compounds and their use as therapeutic drugs
KR102359707B1 (ko) * 2016-07-20 2022-02-09 노파르티스 아게 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
EP3488532B1 (en) 2016-07-20 2025-02-19 Qorvo US, Inc. Method for tuning an antenna with a dvc
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation

Similar Documents

Publication Publication Date Title
JP2020143072A5 (cg-RX-API-DMAC7.html)
JP2022008860A5 (cg-RX-API-DMAC7.html)
ES2374451T3 (es) Bencimidazoles sustituidos como inhibidores de quinasa.
TWI342876B (en) Novel hydroxamates as therapeutic agents
JP2024522494A5 (cg-RX-API-DMAC7.html)
JP2009526072A5 (cg-RX-API-DMAC7.html)
JP2016505512A5 (cg-RX-API-DMAC7.html)
US20160151343A1 (en) Non-flushing niacin analogues, and methods of use thereof
HRP20161121T1 (hr) Terapijska uporaba spojeva koji imaju objedinjenu sert, 5-ht3 i 5-ht1a aktivnost
JP2008522968A5 (cg-RX-API-DMAC7.html)
JP2009510171A5 (cg-RX-API-DMAC7.html)
RU2672910C9 (ru) Гетероароматические соединения как модуляторы фосфоинозитид-3-киназы
IL166855A (en) Annals of compressed pyrimidine with azaleas that inhibit pi3k activity and drugs containing them.
JP2013525291A (ja) 肝がんの治療に使用するための有機化合物
JP2022501429A5 (cg-RX-API-DMAC7.html)
TW201333012A (zh) 咪唑并吡咯啶酮化合物
JP2013523733A5 (cg-RX-API-DMAC7.html)
JP2010509391A5 (cg-RX-API-DMAC7.html)
JP2019505595A5 (cg-RX-API-DMAC7.html)
JP2020507566A5 (cg-RX-API-DMAC7.html)
JP2022540421A5 (cg-RX-API-DMAC7.html)
JP2009530286A (ja) 高血圧症を処置するためならびに脂質を下げるためのチアゾリジンジオン類似体
JP2019502708A5 (cg-RX-API-DMAC7.html)
JP2010527985A5 (cg-RX-API-DMAC7.html)
JP5643213B2 (ja) 肥大性心筋症治療用のホスホジエステラーゼタイプIII(PDEIII)インヒビターまたはCa2+感作剤